A Strategy for the Application of Transgenic Rodent Mutagenesis Assays

Environmental and Molecular Mutagenesis

Volumn 28, Issue 4, 1996, Pages 434-442

  Gorelick, Nancy J ^a   Mirsalis, Jon C ^b  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

lacl; lacZ; Mutagenesis; Transgenic animals

Indexed keywords

ANIMALIA; ESCHERICHIA COLI; RODENTIA; SALMONELLA;

BACTERIAL PROTEIN; BETA GALACTOSIDASE; ESCHERICHIA COLI PROTEIN; LACI PROTEIN, BACTERIA; MUTAGENIC AGENT; REPRESSOR PROTEIN;

ANIMAL; BONE MARROW; CARCINOGEN TESTING; DRUG EFFECT; GENETICS; GERM CELL; HUMAN; LIVER; METHODOLOGY; MOUSE; MUTAGEN TESTING; PRACTICE GUIDELINE; RAT; REVIEW; TISSUE DISTRIBUTION; TRANSGENIC ANIMAL; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BACTERIAL PROTEINS; BETA-GALACTOSIDASE; BONE MARROW; CARCINOGENICITY TESTS; ESCHERICHIA COLI PROTEINS; GERM CELLS; GUIDELINES; HUMANS; LIVER; MICE; MICE, TRANSGENIC; MUTAGENICITY TESTS; MUTAGENS; RATS; REPRESSOR PROTEINS; TISSUE DISTRIBUTION;

EID: 0030344623     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2280(1996)28:4<434::aid-em20>3.0.co;2-f     Document Type: Article

References (83)

1. Aidoo A, Lyn-Cook LE, Mittelstaedt RA, Heflich RH, Casciano DA (1991): Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide. Environ Mol Mutagen 17:141-151.
2. Andrews JL, Walker VE, Upton PB, de Boer JG, Gorelick NJ (1996): Cyclophosphamide-induced mutations are detected at the hprt but not the lacl loci in splenic T-cells of exposed Big Blue® mice. Environ Mol Mutagen 27 (Suppl 27):4.
3. Ashby J, Leigibel U (1992): Transgenic mouse mutation assays: Potential for confusion of genotoxic and non-genotoxic carcinogenesis: A proposed solution. Environ Mol Mutagen 20:145-147.
4. Ashby J, Mirkova E (1987): The activity of MNNG in the mouse bone marrow micronucleus assay. Mutagenesis 2:199-204.
5. Ashby J, Lefevre PA, Tinwell H, Brunborg G, Schmezer P, Pool-Zobel B, Shanu-Wilson R, Holme JA, Soderlund EJ, Gulati D, Wojciechowski JP (1991): The nongenotoxicity to rodents of the potent rodent bladder carcinogens o-anisidine and p-cresidine. Mutat Res 250:115-133.
6. 32P-postlabeling and MutaMouse lacZ-mutation data for DMBA and its K-region sulphur isostere: Comparison with activities observed in standard genotoxicity assays. Mutat Res 292:25-40.
7. Ashby J, Tinwell H, Burnette K, Lefevre PA (1993b): Results for the Big Blue transgenic assay using two genotoxins and a peroxisome proliferator. Environ Mol Mutagen 21(Suppl 22):4.
8. 32P bladder DNA adduction. Carcinogenesis 15:2291-2296.
9. Ashby J, Shelby M, Gorelick NJ (1997): Germ cell study overview and conclusions. Mutat Res (in press).
10. Bentley KS, Sarrif AM, Cimino MC, Auletta AE (1994): Assessing the risk of heritable gene mutation in mammals: Drosophila sex-linked recessive lethal test and tests measuring DNA damage and repair in mammalian germ cells. Environ Mol Mutagen 23:3-11.
11. Boerrigter METI, Dolle MET, Martus H-J, Gossen JA, Vijg J (1995): Plasmid-based transgenic mouse model for studying in vivo mutations. Nature 377:657-659.
12. Brault D, Bouilly C, Renault D, Thybaud V (1996): Tissue-specific induction of mutations by acute oral administration of N-methyl-N′-nitro-N-nitrosoguanidine and β-propiolactone to the Muta-Mouse: Preliminary data on stomach, liver and bone marrow. Mutat Res 360:83-87.
13. Butterworth BE, Conolly RB, Morgan KT (1995): A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. Cancer Lett 93:129-146.
14. Carr GJ, Gorelick NJ (1994): Statistical tests of significance in transgenic mutation assays: Considerations on the experimental unit. Environ Mol Mutagen 24:276-282.
15. Carr GJ, Gorelick NJ (1995): Statistical design and analysis of mutation studies in transgenic mice. Environ Mol Mutagen 25:246-255.
16. Carthew P, Martin EA, White INH, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL (1995): Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital. Cancer Res 55:544-547.
17. Cosentino L, Heddle JA (1996): The test of the concept of neutrality. Environ Mol Mutagen 28:313-316.
18. Cunningham ML, Foley J, Maronpot RR, Matthews HB (1991): Correlation of hepatocellular proliferation with hepatocarcinogenicity induced by the mutagenic noncarcinogen:carcinogen pair 2,6-and 2,4-diaminotoluene. Toxicol Appl Pharmacol 107:562-567.
19. Davies R, Oreffo V, Martin EA, Lilley KS, Dinh PA, Bayliss S, Edwards RE, Carthew P, White INH, Smith LL, Styles JA (1996): Tamoxifen causes gene mutations, DNA adducts and hyperplasia in the livers of Big Blue® transgenic F344 rats. Environ Mol Mutagen 27(Suppl 27):16.
20. Dearfield KL, Auletta AE, Cimino MC, Moore MM (1991): Considerations in the U.S. Environmental Protection Agency's testing approach for mutagenicity. Mutat Res 258:259-283.
21. Douglas GR, Jiao J, Gingerich JD, Gossen JA, Soper LM (1995): Temporal and molecular characteristics of mutations induced by ethylnitrosourea in germ cells isolated from seminiferous tubules and in spermatozoa of lacZ transgenic mice. Proc Natl Acad Sci USA 92:7485-7489.
22. Douglas GR, Jiao J, Gingerich JD, Soper LM, Gossen JA (1996): Temporal and molecular characteristics of lacZ mutations in somatic tissues of transgenic mice. Environ Mol Mutagen 28:317-324.
23. Driscoll KE, Deyo LC, Howard BW, Poynter J, Carter JM (1995): Characterizing mutagenesis in the hprt gene of rat alveolar epithelial cells. Exp Lung Res 21:941-956.
24. Dycaico MJ, Provost GS, Kretz PL, Ransom SL, Moores JC, Short JM (1994): The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat Res 307:461-478.
25. Dycaico MJ, Stuart GR, Tobal GM, de Boer JG, Glickman BW, Provost GS (1996): Species-specific differences in hepatic mutant frequency and spectrum among lambda/lacl transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis, 17:2347-2356.
26. Gibson DP, O'Kelly JA, Aardema MJ, Gorelick NJ (1995): Comparison of assessment of micronuclei and mutations in lacl transgenic mice. Environ Mol Mutagen 25(Suppl 25):18.
27. Gondo Y, Shioyama Y, Nakao K, Katsuki M (1996): A novel positive detection system of in vivo mutations in rpsL (strA) transgenic mice. Mutat Res 360:1-14.
28. Gorelick NJ (1995): Overview of mutation assays in transgenic mice for routine testing. Environ Mol Mutagen 25:218-230.
29. Gorelick NJ, Thompson ED (1994): Overview of the workshops on statistical analysis of mutation data from transgenic mice. Environ Mol Mutagen 23:12-16.
30. Gorelick NJ, Andrews JL, Gu M, Glickman BW (1995a): Mutational spectra in the lacl gene in skin from 7,12-dimethylbenz[a]-anthracene-treated and untreated transgenic mice. Mol Carcinogen 14:53-62.
31. Gorelick NJ, O'Kelly JA, Biederman KA, de Boer JG (1995b): UVA-and UVB-induced mutational spectra in the lacl gene from transgenic mouse skin. Presented at Photocarcinogenesis: Mechanisms, Models and Human Health Implications, October 1995, Washington DC.
32. Gossen JA, Vijg J (1990): Transgenic mice as a model to study gene mutations: Application as a short-term mutagenicity assay. Prog Clin Biol Res 340A:347-354.
33. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T (1993): Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924.
34. Hayward JJ, Shane BS, Tindall KR, Cunningham ML (1995): Differential in vivo mutagenicity of the carcinogen/non-carcinogen pairs 2,4- and 2,6-diaminotoluene. Carcinogenesis 16:2429-2433.
35. Heddle JA, Shaver-Walker P, Tao KS, Zhang XB (1995): Treatment protocols for transgenic mutation assays in vivo. Mutagenesis 10:467-470.
36. Hirsimaki P, Hirsimaki Y, Nieminen L, Payne BJ (1993): Tamoxifen induces hepatocellular carcinoma in rat liver - a 1-year study with 2 antiestrogens. Arch Toxicol 67:49-54.
37. Huff JE, Melnick RL, Solleveld HA, Haseman JK, Powers M, Miller RA (1985): Multiple organ carcinogenicity of 1,3-butadiene in B6C3F1 mice after 60 weeks of inhalation exposure. Science 227:548-549.
38. IARC (1993): "Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Amines and Mycotoxins." IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, vol 56. Lyon: International Agency for Research on Cancer, pp 245-395.
39. Jansen JG, Mohn GR, Vrieling H, van Teijlingen CMM, Lohman PHM, van Zeeland AA (1994): Molecular analysis of hprt gene mutations in skin fibroblasts of rats exposed in vivo to N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea. Cancer Res 54:2478-2485.
40. Johnson TD, Carr GJ, Gorelick NJ (1996): A program for testing for trend in transgenic mouse mutation assays. Presented at Transgenic Animals in Mutation Research meeting, Sidney, B.C., March 20-23, 1996.
41. Jones IM, Burkhart-Schultz K, Strout CL, Crippen TL (1987): Factors that affect the frequency of thioguanine-resistant lymphocytes in mice following exposure to ethylnitrosourea. Environ Mutagen 9:317-329.
42. Kohler S, Provost S, Kretz P, Dycaico M, Sorge J, Short JM (1990): Development of a short-term, in vivo mutagenesis assay: The effects of methylation on the recovery of a lambda phage shuttle vector from transgenic mice. Nucleic Acids Res 18:3007-3013.
43. Leach EG, Narayanan L, Havre PA, Gunther EJ, Yeasky TM, Glazer PM (1996): Tissue specificity of spontaneous point mutations in λsupF transgenic mice. Environ Mol Mutagen 28:458-463.
44. Martus J-H, Dollé MET, Gossen JA, Boerrigter METI, Vijg J (1995): Use of transgenic mouse models for studying somatic mutations in aging. Mutat Res 338:203-213.
45. Mirsalis J (1993): Dosing regimens for transgenic animal mutagenesis assays. Environ Mol Mutagen 21:118-119.
46. Mirsalis JC, Tyson CK, Butterworth BE (1982): Detection of carcinogens in the in vivo/in vitro hepatocyte DNA repair assay. Environ Mutagen 4:553-562.
47. Mirsalis JC, Monforte JA, Winegar RA (1994): Transgenic animal models for measuring mutations in vivo. Crit Rev Toxicol 24:255-280.
48. Myhr B, Suzuki T, Intehar K, Khouri H, Custer L, Brusick D (1992): Chemical induction of peripheral blood micronuclei and bone marrow mutations in MutaMouse. Environ Mol Mutagen 19(Suppl 20):45.
49. Nohmi T, Katoh M, Suzuki H, Matsui M, Yamada M, Watanabe M, Suzuki M, Horiya N, Ueda O, Shibuya T, Ikeda H, Sofuni T (1996): A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections. Environ Mol Mutagen 28:464-469.
50. Organizing Committee of Collaborative Study Group on the Transgenic Mutation Assay in JEMS/MMS (1996): Organ variation in the mutagenicity of ethylnitrosourea in Muta Mouse: Results of the collaborative study on the transgenic mutation assay by JEMS/ MMS. Environ Mol Mutagen 28:363-375.
51. Piegorsch WW, Lockhart A-MC, Margolin BH, Tindall KR, Gorelick NJ, Short JM, Carr GJ, Thompson ED, Shelby MD (1994): Sources of variability in data from a lacl transgenic mouse mutation assay. Environ Mol Mutagen 23:17-31.
52. Piegorsch WW, Margolin BH, Shelby MD, Johnson A, French JE, Tennant RW, Tindall KR (1995): Study design and sample sizes for a lacl transgenic mouse mutation assay. Environ Mol Mutagen 25:231-245.
53. Piegorsch WW, Lockhart AC, Carr GJ, Margolin BH, Brooks T, Douglas GR, Liegibel UM, Suzuki T, Thybaud V, van Delft JHM, Gorelick NJ (1997): Sources of variability in data from a positive selection lacZ transgenic mouse mutation assay: An interlaboratory study. Mutat Res, in press.
54. Provost GS, Short JM (1994): Characterization of mutations induced by ethylnitrosourea in seminiferous tubule germ cells of transgenic B6C3F1 mice. Proc Natl Acad Sci USA 91:6564-6568.
55. Recio L, Osterman-Golkar S, Csanady GA, Turner MJ, Myhr B, Moss O, Bond JA (1992): Determination of mutagenicity in tissues of transgenic mice following exposure to 1,3-butadiene and N-ethyl-N-nitrosourea. Toxicol Appl Pharmacol 117:58-64.
56. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE (1992): Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339:943-946.
57. Sargent LM, Dragan TP, Bahnub N, Wiley JE, Sattler CA, Schroeder P, Sattler GL, Jordan VC, Pilot HC (1994): Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 54:3357-3360.
58. Shaver-Walker PM, Urlando C, Tao KS, Zhnag XB, Heddle JA (1995): Enhanced somatic mutation rates induced in stem cells of mice by low chronic exposure to ethylnitrosnurea. Proc Natl Acad Sci USA 92:11470-11474.
59. Sisk SC, Bond JA, Recio L (1993): Determination of mutagenicity in tissues of lacl transgenic mice after inhalation exposure to 1,3-butadiene. Toxicologist 13:411.
60. Sisk SC, Pluta LJ, Bond JA, Recio L (1994): Molecular analysis of lacl mutants from bone marrow of B6C3F1 transgenic mice following inhalation exposure to 1,3-butadiene. Carcinogenesis 15:471-477.
61. Skopek TR, Kort KL, Marino DR (1995): Relative sensitivity of the endogenous hprt gene and lacl transgene in ENU-treated Big Blue B6C3F1 mice. Environ Mol Mutagen 26:9-15.
62. Skopek TR, Kort KL, Marino DR, Mittal LV, Umbenhauer DR, Laws GM, Adams SP (1996): Mutagenic response of the endogenous hprt gene and lacl transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Environ Mol Mutagen 28:376-384.
63. Sofuni T, Suzuki T, Hayashi M (1996): Initial consideration for use of transgenic mutation assays in a regulatory submission. Environ Mol Mutagen 28:443-446.
64. Styles JA, Davies A, Lim CK, de Matteis F, Stanley LA, While INH, Yuan Z-X, Smith LL (1994): Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15:5-9.
65. Suzuki T, Hayashi M, Sofuni T, Myhr BC (1993): The concomitant detection of gene mutation and micronucleus induction by mitomycin C in vivo using lacZ transgenic mice. Mutat Res 285:219-224.
66. Tao KS, Heddle JA (1994): The accumulation and persistence of somatic mutations in vivo. Mutagenesis 9:187-191.
67. Tao KS, Urlando C, Heddle JA (1993): Comparison of somatic mutation in a transgenic versus host locus. Proc Natl Acad Sci USA 90:10681-10685.
68. Thompson ED, Osterhues MA (1995): Effect of expression period on dimethylbenzanthracene-induced mutations in skin of Big Blue mice. Environ Mol Mutagen 25(Suppl 25):52.
69. Thompson ED, Gorelick NJ, Binder RL, Myhr BC, Putman DL (1992): Interlaboratory comparison of dimethylbenzanthracene-induced mutations in skin of Muta™Mouse and the Big Blue™ mouse. Environ Mol Mutagen 19(Suppl 20):64.
70. Tice RR, Shelby MD (1994): Report of in vivo subgroup. Mutat Res 312:287-292.
71. Tinwell H, Liegibel U, Krebs O, Schmezer P, Favor J, Ashby J (1995): Comparison of lacl and lacZ transgenic mouse mutation assays: An EU-sponsored interlaboratory study. Mutat Res 335:185-190.
72. Tucker MJ, Adams HK, Patterson JS (1984): Tamoxifen. In: Laurence DR, McLean AEM, Weatherall M (eds): "Safety Testing of New Drugs." New York: Academic Press, pp 125-161.
73. US Department of Health, Education and Welfare (1979): Bioassay of 2,4-diaminotoluene for possible carcinogenicity. NCI Carcinogenesis Technical Report Series 162, US Department of Health, Education and Welfare, Public Health Service, Bethesda, MD: National Institutes of Health.
74. US Department of Health, Education and Welfare (1980): Bioassay of 2,6-toluenediamine hydrochloride for possible carcinogenicity. NCI Carcinogenesis Technical Report Series 200, US Department of Health, Education and Welfare, Public Health Service. Bethesda, MD: National Institutes of Health.
75. van Delft JHM, Baan RA (1995): Germ cell mutagenesis in lacZ transgenic mice treated with ethylnitrosourea; comparison with specific-locus test. Mutagenesis 10:209-214.
76. Walker VE, Gorelick NJ, Andrews JL, Craft TR, deBoer JG, Glickman BW, Skopek TR (1996): Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacl loci in splenic lymphocytes of exposed lacl transgenic mice. Cancer Res, 56:4654-4661.
77. White INH, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH (1992): Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203.
78. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP (1993): The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317.
79. Winegar RA, Lutze LH, Hamer JD, O'Loughlin KG, Mirsalis JC (1994): Radiation-induced point mutations, deletions and micronuclei in lacl transgenic mice. Mutat Res 307:479-487.
80. Winton DJ, Blount MA, Ponder BAJ (1988): A clonal marker induced by mutation in mouse intestinal epithelium. Nature 333:443-446.
81. Wogan GN (1973): Aflatoxin carcinogenesis. In: Busch H (ed): "Methods in Cancer Research," vol 7. New York: Academic Press, pp 309-344.
82. Young RR, Rogers BJ, Provost GS, Short JM, Putman DL (1995): Interlaboratory comparison: Liver spontaneous mutant frequency from lambda/lacl transgenic mice (Big Blue®). Mutat Res 327:67-73.
83. Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K (1988): Salmonella mutagenicity tests. IV. Results from the testing of 300 chemicals. Environ Mol Mutagen 11(Suppl 12):1-158.